Approach to the treatment-naïve patient with HCV genotype 1 infection.
Journal Article (Journal Article;Review)
In May 2011, the protease inhibitors boceprevir and telaprevir were approved in combination with peginterferon-α and ribavirin for the treatment of genotype 1 chronic hepatitis C virus infection in the United States. These regimens brought substantial improvements in sustained virologic response rates, especially for treatment-naïve patients. This article reviews the approach to therapy with these genotype 1 treatment-naïve patients.
- Muir, AJ
- December 2012
Volume / Issue
- 26 / 4
Start / End Page
- 893 - 901
Electronic International Standard Serial Number (EISSN)
Digital Object Identifier (DOI)
- United States